JP2015526074A - Ｊａｋ／ｓｔａｔ阻害剤に対する治療反応の予測 - Google Patents

Ｊａｋ／ｓｔａｔ阻害剤に対する治療反応の予測 Download PDF

Info

Publication number
JP2015526074A
JP2015526074A JP2015524417A JP2015524417A JP2015526074A JP 2015526074 A JP2015526074 A JP 2015526074A JP 2015524417 A JP2015524417 A JP 2015524417A JP 2015524417 A JP2015524417 A JP 2015524417A JP 2015526074 A JP2015526074 A JP 2015526074A
Authority
JP
Japan
Prior art keywords
jak
biomarkers
stat
cish
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526074A5 (cg-RX-API-DMAC7.html
Inventor
ツァオ，アレキサンダー
モリセー，マイケル
ソンキン，デミトリー
パルマー，マイケル
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015526074(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2015526074A publication Critical patent/JP2015526074A/ja
Publication of JP2015526074A5 publication Critical patent/JP2015526074A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015524417A 2012-07-27 2013-07-24 Ｊａｋ／ｓｔａｔ阻害剤に対する治療反応の予測 Pending JP2015526074A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261676484P 2012-07-27 2012-07-27
US61/676,484 2012-07-27
US201361769271P 2013-02-26 2013-02-26
US61/769,271 2013-02-26
US201361829327P 2013-05-31 2013-05-31
US61/829,327 2013-05-31
PCT/US2013/051824 WO2014018632A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Publications (2)

Publication Number Publication Date
JP2015526074A true JP2015526074A (ja) 2015-09-10
JP2015526074A5 JP2015526074A5 (cg-RX-API-DMAC7.html) 2016-09-08

Family

ID=48906529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015524417A Pending JP2015526074A (ja) 2012-07-27 2013-07-24 Ｊａｋ／ｓｔａｔ阻害剤に対する治療反応の予測

Country Status (18)

Country Link
US (1) US20150299796A1 (cg-RX-API-DMAC7.html)
EP (1) EP2877596A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015526074A (cg-RX-API-DMAC7.html)
KR (1) KR20150038241A (cg-RX-API-DMAC7.html)
CN (1) CN104508149A (cg-RX-API-DMAC7.html)
AU (2) AU2013295855A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015001521A2 (cg-RX-API-DMAC7.html)
CA (1) CA2880198A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015000192A1 (cg-RX-API-DMAC7.html)
HK (1) HK1205198A1 (cg-RX-API-DMAC7.html)
IL (1) IL236897A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015001269A (cg-RX-API-DMAC7.html)
PH (1) PH12015500169A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015106714A (cg-RX-API-DMAC7.html)
SG (1) SG11201500261VA (cg-RX-API-DMAC7.html)
TN (1) TN2015000019A1 (cg-RX-API-DMAC7.html)
TW (1) TW201409030A (cg-RX-API-DMAC7.html)
WO (1) WO2014018632A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
CR20170410A (es) 2015-03-10 2017-11-08 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del "estimulador del gen interferon"
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106544414A (zh) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 一种检测肺癌脑转移样本中stat3和lck的方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048123A2 (en) * 2008-10-20 2010-04-29 Eckhardt S Gail Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US20060194275A1 (en) * 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
NZ597140A (en) * 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
BR112013013684A2 (pt) * 2010-12-03 2016-09-06 Ym Biosciences Australia Pty tratamento das condiçóes mediadas por jak-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048123A2 (en) * 2008-10-20 2010-04-29 Eckhardt S Gail Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 111, no. 12, JPN6017020883, 2008, pages 5663 - 5671, ISSN: 0003960844 *
BLOOD, vol. 115, no. 15, JPN6017020884, 2010, pages 3109 - 3117, ISSN: 0003960845 *
BLOOD, vol. 118, no. 21, JPN6018021073, 2011, pages 1744, ISSN: 0003960841 *
CANCER RES., vol. 71, no. 14, JPN6017020882, 2011, pages 5020 - 5029, ISSN: 0003960843 *
LEUKEMIA, vol. 26, no. 2, JPN6017020886, February 2012 (2012-02-01), pages 280 - 288, ISSN: 0003960842 *
N. ENGL. J. MED., vol. 366, no. 9, JPN6017020885, March 2012 (2012-03-01), pages 787 - 798, ISSN: 0003960846 *

Also Published As

Publication number Publication date
BR112015001521A2 (pt) 2017-11-07
TW201409030A (zh) 2014-03-01
IL236897A0 (en) 2015-03-31
AU2013295855A1 (en) 2015-02-12
US20150299796A1 (en) 2015-10-22
KR20150038241A (ko) 2015-04-08
EP2877596A1 (en) 2015-06-03
WO2014018632A1 (en) 2014-01-30
AU2017204894A1 (en) 2017-08-03
HK1205198A1 (en) 2015-12-11
RU2015106714A (ru) 2016-09-20
CL2015000192A1 (es) 2015-06-26
MX2015001269A (es) 2015-05-08
SG11201500261VA (en) 2015-02-27
CA2880198A1 (en) 2014-01-30
TN2015000019A1 (en) 2016-06-29
CN104508149A (zh) 2015-04-08
PH12015500169A1 (en) 2015-03-16

Similar Documents

Publication Publication Date Title
JP2015526074A (ja) Ｊａｋ／ｓｔａｔ阻害剤に対する治療反応の予測
EP2715366B1 (en) Biomarkers for hedgehog inhibitor therapy
US11118232B2 (en) Methods of detecting DDR2 mutations
US10519507B2 (en) Method for detecting T-cell lymphoma
US9353419B2 (en) Biomarkers for IAP inhibitor therapy
WO2014190927A1 (zh) 胰腺神经内分泌肿瘤易感基因位点及检测方法和试剂盒
US20120157342A1 (en) Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
HK1241934B (en) Method of determining pik3ca mutational status in a sample
NZ617421B2 (en) Biomarkers for hedgehog inhibitor therapy
HK1241934A1 (en) Method of determining pik3ca mutational status in a sample

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190122